Race Oncology (ASX:RAC) completed a drug discovery program targeting the Fat and Obesity associated (FTO) protein at Monash University's Fragment Platform, according to a Thursday filing with the Australian bourse.
The program used nuclear magnetic resonance screening to identify 39 chemical candidates that bind specifically to the FTO protein, the filing said.
The FTO protein is a key regulator in ribonucleic acid (RNA) epigenetics. Loss of control of RNA epigenetics is linked to several cancers and metabolic diseases.
The identification of the chemical candidates by Race Oncology provides a platform for developing new FTO-targeting drugs, the filing said.
Race Oncology plans to advance these candidates into a hit-to-lead medicinal chemistry program, though a final decision has not yet been made on progressing this expensive phase.
The company's shares rose almost 3% in recent Thursday trade.
Price (AUD): $1.40, Change: $+0.04, Percent Change: +2.94%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。